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Abstract 
Background: In constructing or appraising a health economic model, an early consideration is whether the model‑
ling approach selected is appropriate for the given decision problem. Frameworks and taxonomies that distinguish 
between modelling approaches can help make this decision more systematic and this study aims to identify and 
compare the decision frameworks proposed to date on this topic area.
Methods: A systematic review was conducted to identify frameworks from peer‑reviewed and grey literature 
sources. The following databases were searched: OVID Medline and EMBASE; Wiley’s Cochrane Library and Health 
Economic Evaluation Database; PubMed; and ProQuest.
Results: Eight decision frameworks were identified, each focused on a different set of modelling approaches and 
employing a different collection of selection criterion. The selection criteria can be categorized as either: (i) structural 
features (i.e. technical elements that are factual in nature) or (ii) practical considerations (i.e. context‑dependent attrib‑
utes). The most commonly mentioned structural features were population resolution (i.e. aggregate vs. individual) 
and interactivity (i.e. static vs. dynamic). Furthermore, understanding the needs of the end‑users and stakeholders was 
frequently incorporated as a criterion within these frameworks.
Conclusions: There is presently no universally‑accepted framework for selecting an economic modelling approach. 
Rather, each highlights different criteria that may be of importance when determining whether a modelling approach 
is appropriate. Further discussion is thus necessary as the modelling approach selected will impact the validity of 
the underlying economic model and have downstream implications on its efficiency, transparency and relevance to 
decision‑makers.
Keywords: Decision analysis, Health economic evaluation, Systematic review, Decision trees, State‑transition models, 
Markov model, Microsimulation, Agent‑based models, System dynamics, Compartmental models
© 2015 Tsoi et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The use of decision-analytic modelling to estimate the 
cost-effectiveness of health care interventions is becom-
ing widespread to inform health policy decision-making. 
A model, referred to in this article, is defined as the use of 
analytical methodology to quantitatively compare health 
technologies. Models may have a range of uses including 
extrapolating from primary data sources and transferring 
results from one jurisdiction to another [1]. By incorpo-
rating event probabilities, resource utilization, costs and 
patient outcomes, a model synthesizes the data to iden-
tify the best option for decision-makers.
However, with the growing reliance on economic eval-
uations to support decision-making, concerns have risen 
on the validity, reliability and comparability of the results 
generated from such models [1]. To respond to these crit-
icisms, the research community has focused considerable 
efforts in setting best practice guidelines for the devel-
opment and conduct of health economic models. This 
is evident from the guidelines published by respective 
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health technology assessment (HTA) agencies (e.g. 
Canadian Agency for Drugs and Technologies in Health 
(CADTH) [2]) and from non-profit research organiza-
tions (e.g. International Society For Pharmacoeconomics 
and Outcomes Research (ISPOR) [3–5]).
With the growing diversity of modelling approaches 
available (Table  1), a particular question is the relative 
merits of each approach in health economic modelling. 
Historically and still to date, decision trees and Markov 
cohort models are the most commonly used approaches 
in economic evaluation. However, due to their limita-
tions, awareness has grown on alternative modelling 
approaches. Guidance documents recommend trans-
parent reporting of a modeller’s rationale for selecting a 
model type, although it may not always be clear which 
approach would be most suitable for a given decision 
problem. This is an important issue since each approach 
can introduce constraints to a model’s development and 
its conceptualization in terms of what elements can be 
captured and the ease to which they can be incorporated 
into the model [6]. This may lead to a different focus on 
the decision problem and, thereby, generate conflicting 
results and diverging policy recommendations [7].
To provide guidance on how to select a particular mod-
elling approach, frameworks have emerged that catego-
rize and distinguish between them. However, no attempt 
has been made to compare and contrast these frame-
works. The purpose of this paper is therefore to conduct 
a systematic literature review to identify and critically 
appraise these published frameworks.
Methods
Search methods
A literature search was performed for articles published 
up to January 21, 2014 with the following bibliographic 
databases searched: OVID Medline (1946-present; In-
Process & Other Non-Indexed Citations) and EMBASE 
(1996-present); Wiley’s Cochrane Library (Issue 1 of 12, 
Apr 2014) and Health Economic Evaluation Database; 
PubMed (for non-Medline records); and ProQuest Dis-
sertations. Controlled vocabulary terms, such as the 
National Library of Medicine’s Medical Subject Headings 
(MeSH), and keywords were used to construct the search 
strategy (Additional file 1, Additional file 2). The elec-
tronic search was supplemented by cross-checking the 
bibliographies of relevant publications and grey literature 
searches (e.g. working papers, commissioned reports, 
policy documents, websites).
Selection of relevant articles
Records were screened for inclusion based on the pre-
defined criteria presented in Additional file 3. To be 
included, a paper had to describe, in whole or in part, a 
decision framework (e.g. algorithm, taxonomy) on how 
to select between economic modelling approaches in the 
context of health care policy decision-making. Studies 
were limited to those published in English.
The titles and abstracts of the records identified from 
the bibliographic search were initially screened for rel-
evance by one reviewer (B.T.) with a 50% random check 
conducted by a second independent reviewer (J.J.). If 
either reviewers identified a citation as being potentially 
relevant, its full-text was obtained. In the second phase of 
screening, one reviewer (B.T.) assessed the full-text ver-
sion of all included articles, with a second independent 
reviewer (J.J.) completing a 50% random sample. Any dis-
crepancies at this stage were resolved through discussion 
and consensus.
Data extraction
A standardized data abstraction form was developed to 
extract data from the relevant studies. The form captured: 
bibliographic information (e.g. author, year); framework 
type (e.g. flow-chart, table); framework description, includ-
ing its selection criteria; and the main conclusions. Their 
evolution and history, if discussed, was further noted.
The selection criteria specific to each decision frame-
work were identified. These had to be present within the 
framework; criteria that were simply mentioned in the 
paper but not explicitly incorporated into the framework 
were excluded. These criteria were separated into either 
structural features or practical considerations. Struc-
tural features were defined as those relating to principles 
or theories behind a model. These are the technical ele-
ments that lay bare the intricacies of modelling concepts 
and the nature of the decision problem will dictate the 
structural features desired within a model. Practical con-
siderations are defined as elements that impact the effec-
tiveness or feasibility of developing and constructing a 
model and are, to a degree, context-dependent.
Data analysis
Data were analyzed and synthesized with the intent to:
i. Understand the evolution of the frameworks;
ii. Tabulate and identify the frequency to which selec-
tion criteria were discussed across these frameworks;
iii. Evaluate the extent to which the frameworks agree 
or disagree on the structural features specific to each 
modelling approach.
Results
Of the 3,342 unique publications identified from the 
literature search, eight met the full inclusion criteria 
(Figure  1). Most studies were excluded either because 
it made no mention to decision-analytic modelling or 
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Table 1 Description of modelling approaches employed in health economic evaluation
Model approach Description (key terminology italicized)
Decision tree Decision trees embody the central paradigm of decision analysis. Events in the tree are typically arranged in temporal order 
from left to right. Decisions are broken down into three components:
(i) Decision node decision point between competing strategies
(ii) Chance node consequence to a given decision. Typically indicates point where two or more alternative chance events for 
a patient are possible. May contain sequential chance events
(iii) Terminal node Terminal branch, representing the value of a particular strategy
Branches connect the nodes and represent the pathways through the tree. At each chance node, the probabilities of each 
consequence will determine the proportion of patients progressing down each unique path
Consequences such as costs and effects of events and decisions may be attributed at each chance node of the tree or 
accumulated at the terminal nodes. The expected effect and/or costs associated with each treatment option or branch 
is estimated by ‘rolling’ back the tree whereby a weighted average of the value of all branches emanating from a decision 
node is calculated
Markov cohort model Markov cohort models describe the transition of patients as they move through health states over time. Health states are 
mutually exclusive events, representing the entirety of the disease process and patients are assumed to be in one of a 
finite number of health states (known as the unitary state requirement). Patients within the same health state are assumed 
homogeneous
Movement between health states are governed by transition probabilities that occur only once per Markov cycle (i.e. a 
defined time period). The transition probabilities depend only on the starting state and not on any of the previous health 
states (i.e. memoryless assumption)
The model is run over many cycles to build a profile of how many patients are in each state of the model over time
Estimates of costs and health outcomes are attached to the states within the model. Cycle sum are calculated as the 
weighted average of the proportion of a cohort in a health state multiplied by the value for that particular health state, 
summing across all health states. Expected costs and QALYs are then calculated by summing all cycle sums over the 
model’s time horizon
Markov microsimulation Markov microsimulation simulates individual patients over time. As individuals are modelled separately, microsimulation can 
store information as to what has happened to the individual (i.e. memory). Similarly, as individuals are modelled, there is 
no need to assume homogeneity between patients. The unitary state requirement remains as patients can only be in one 
of a finite number of health states during each cycle. Transitions govern patient prognosis and are calculated by model 
parameters that reflect actual event/transition rates and may be conditional on previous and current risk factors and 
historical outcomes. Transitions occur only once per cycle
Consequences such as costs and effects of events are attributed to health states and are summed over each cycle. Each 
patient has their own respective costs and outcome following a run through the model and the expected costs and 
QALYs can be calculated as the average from a large number of patients that have gone through the model
Discrete event simulation Discrete event simulation describes the flow of entities through the treatment system. Entities are objects, such as individu‑
als, that may interact indirectly with other entities within the system when waiting for resources to become available. Enti‑
ties may be given attributes, such as characteristics or memory, which may influence their route through the simulation 
and/or the length of time between events. Another important concept is resources, representing an object that provides 
service to a dynamic entity
Life (and disease) histories of individuals are simulated one‑by‑one or simultaneously. If simulated simultaneously, one can 
model entity interactions or resource competition, thereby, explicitly embedding the effects of queues
Consequences such as costs and effects can be attached to events, resource use or time with a particular condition
Agent‑based model This approach focuses on the agent. Agents are aware of their state and follow decision rules on how to communicate and 
interact with other agents or their environment. Agents are flexible as they may adapt over time, learn from experience 
and/or exist within a hierarchical structure. From simple rules governing individual actions and communication, complex 
behaviour may emerge
As agents exist within a network, social network analysis may be used to examine interventions that impact inter‑agent 
relationships and communication. It further provides a means for spatial considerations and can examine interventions 
that have a geographic impact
Consequences such as costs and effects can be attributed to the events or patient attributes
System dynamics model The causal loop diagram provides a qualitative visualization of a system’s structure. Its basic building block is the feedback 
loop, describing change at one point within a system that triggers a cascading series of changes that ripple through and 
eventually returns in some form to either reinforce or push back against that original change. Complex behaviour may 
emerge from the interaction of multiple feedback loops
The system dynamics model is quantified by stock and flow diagrams. As per its name, these diagrams consist of two main 
variable types: stocks (also referred to as levels or state or accumulations) and flows (i.e. rates at which stocks are either 
drained or replenished). Movement between stocks is defined by the rate of flow and, together, a system’s behaviour may 
be described through a set of differential equations
Costs and outcomes may be attributed to the time‑in‑stocks or movements between stocks that are continuously updated
Compartmental model Compartmental models are historically used to model the epidemiology of infectious disease. The population is divided 
into various compartments, representing their average state. Individuals within a single compartment are considered 
homogeneous. Most commonly, it contains compartments of the population whom are at different stages of the illness 
(e.g. susceptible, exposed, infectious, recovered).
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it did not present a selection framework to guide the 
choice between modelling approaches. Overall, the 
agreement between independent reviewer for study 
inclusion was considered moderate (Cohen’s kappa 
0.60).
Table  2 provides an overview of the decision frame-
works in terms of the country of publication, the frame-
work’s focus and the modelling approaches that were 
covered. All decision frameworks were published in the 
past 10 years with two specific to infectious diseases [6, 
8] and the remainder being generic/non-disease specific 
[7, 9–13]. Each framework covered different model types, 
although all of them involved a decision between a tradi-
tional modelling approach (i.e. decision tree and Markov 
cohort model) and one or more alternative approaches 
(e.g. discrete event simulation; agent-based model; sys-
tem dynamics).
Decision frameworks were visually represented by 
flow charts [6, 9, 12, 13], radar graphs [7], or tables [8, 
10, 11] and Table 3 further details the selection criteria 
that were considered within each framework. The defi-
nition of common structural features and practical 
consideration that were identified from this review of 
frameworks are presented in Table  4. The structural 
elements include: the resolution of the population; 
the capture of first-order uncertainty; the nature of 
the interactions; the handling of resource constraint; 
and the dimension of time. From Table  3, it was found 
that the most common structural features considered 
amongst these frameworks were interactivity (i.e. static 
vs. dynamic) and population resolution (i.e. aggregate or 
individual) (n = 6/8; 75%), followed by how time is han-
dled (n  =  4/8; 50%) (Table  3). Practical considerations 
(Table  4b) were explicitly included within most flow-
charts and the most common practical consideration 
were the end-user requirements and simplicity (n = 3/8; 
37.5%) (Table 3).
Below, a narrative summary of each framework is pre-
sented. A copy of each decision framework can be further 
found in Additional file 4.





























(n = 3342) 
Records excluded 
(n = 3217) 
Full-text arcles assessed for 
eligibility 
(n = 125) 
Full-text arcles excluded, 
with reasons (117) 
No menon of decision-
analyc modelling (n=15) 
Does not present a 
framework (n=112) 
Studies reporng a 
framework on how to 
select modelling approach 
(n = 8) 
Grey literature sources 
(n =2) 
Figure 1 PRISMA diagram of literature search for articles on decision frameworks to select the appropriate modelling approach.
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Generic frameworks
The first paper within the health care field on this topic 
was by Barton et al. [9]. Based on the following four cri-
teria, their flowchart assists in the selection between 
decision tree, Markov cohort model, Markov microsim-
ulation, discrete event simulation and system dynamics: 
(i) interactivity—importance of capturing interaction 
between patients; (ii) population resolution—the neces-
sity of individual-level modelling; (iii) validity—the ade-
quacy of pathways represented by a decision tree; and (iv) 
simplicity—the number of states required in a Markov 
cohort model. The authors highlight the trade-off 
between simplicity and clinical validity. They recommend 
a more complex and computational-demanding model 
only if it provides a more accurate representation of the 
decision problem and leads to more valid results [9]. Sim-
plification, according to the authors, may involve fixing 
one or more parameters in the model and two conditions 
may justify such a practice: when the results are robust to 
variation with that particular set of parameters or if the 
parameter is derived from good and accurate data.
Brennan et  al. [10] have proposed a taxonomy 
table describing the relationships between modelling 
approaches according to their structural features. The 
columns in their taxonomy highlight the assumptions of 
population resolution; expected value/memory and first-
level uncertainty while the rows describes the interac-
tion between individuals and the handling of time. Each 
cell in the table lists the modelling approach with those 
corresponding structural features. Some of the model 
structures described in this taxonomy can be consid-
ered subclassification of specific modelling approaches. 
For instance, depending on the dimension of time and 
first-order uncertainty, system dynamics was separated 
into finite difference equation system dynamics, ordi-
nary differential equation system dynamics, discrete time 
Markov chain model and continuous time Markov chain 
model. The authors state that the identification of health 
states and risk factors, and their underlying relationships 
should precede the selection of a modelling approach. If 
multiple approaches are suitable, the simplest model that 
accurately addresses the decision problem should be cho-
sen with further consideration on practical factors such 
as software availability, implementation skills, time con-
straints and end-user requirements [10].
Chick [11] simplifies Brennan’s proposed taxonomy by 
removing the rows specific to the dimension of interac-
tivity; thereby, reducing the subclassification of certain 
modelling approaches seen in Brennan et  al’s original 
taxonomy (i.e. microsimulation, system dynamics). How-
ever, it remains unclear why, for one set of features (i.e. 
stochastic Markovian individual discrete time), the cell 
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any particular modelling approach [11]. For this particular 
set of features, Brennan et al’s described the model struc-
ture as: ‘discrete-time individual event history model’.
Similarly, Heeg et  al. [7] adapts Brennan’s [10] frame-
work. However, rather than using a taxonomy table, they 
displayed their framework as a radar diagram that ranks 
the relative ability of decision tree, Markov cohort model, 
discrete event simulation and Markov microsimulation 
in addressing a collection of selection criterion—includ-
ing practical considerations. Each spoke on the radar 
diagram represents a particular selection criterion and 
modelling approaches that are better at addressing that 
criterion appear further away from the origin of the radar 
diagram. Their framework incorporates all of the techni-
cal features proposed by Brennan although different ter-
minologies are employed: ‘randomness’ is now referred to 
as ‘variability’ (i.e. first order uncertainty) while ‘expected 
value’ is referred to as ‘memory’ [7]. An additional tech-
nical feature included is the interaction due to covariates 
and nonlinear associations between individual risk fac-
tors and outcomes. The following practical considera-
tions were also included in their framework: time (i.e. to 
collect data, build and simulate the model); experience 
and validity (i.e. clinical representativeness) (Table 3) [7].
An independent framework developed by Cooper et al. 
[12] similarly intertwined practical and structural con-
siderations (Table 3) to help guide the decision between 
Markov cohort model, decision tree and discrete event 
simulation. The authors state that the nature and the 
complexity of the disease, and the health care interven-
tion, may influence which structural features to con-
sider (e.g. interaction between individuals; queuing 
and resource constraints) [12]. Rather than considering 
population resolution explicitly as a structural feature, 
this framework mentioned the impact of dimensional-
ity in terms of the differences in time required to build 
and conduct simulations between aggregate-level and 
individual-level models. Outside of their framework, the 
modeller’s experience and data availability were addi-
tional factors that, together, may impact the speed and 
the ease of model development. The authors recommend 
that the analysis should be built based on the simplest 
model that can adequately address the research ques-
tion [12]. A unique trait in Cooper’s framework is that 
it recognizes that modelling may not always be possible, 
and further incorporates an ‘abandon’ scenario when it is 
futile to pursue modelling given the disconnect between 
practical constraints and the desired technical attributes 
(e.g. significant heterogeneity and/or when queuing or 
interaction between individuals is important). In such 
cases, when the practical elements and the structural fea-
tures conflict, construction of a model should be stopped 
until such issues are resolved [12].
By moving through a series of decisions pertaining 
mainly to the desired structural features, Stahl’s [13] 
hierarchical flowchart filters the choice of modelling 
approaches down to one to two suitable ones. Similar to 
Cooper [12], Stahl also advocates that simplicity should 
be a guiding principle—referring to it as, ‘keep it simple 
stupid (KISS)’ with a model only as complex as necessary 
for the question(s) of interest [13].
Infectious disease specific frameworks
Brennan et al’s framework [10] was modified by another 
group of researchers for the evaluation of vaccines. Mod-
els were categorized according to three structural fea-
tures: population resolution; first-order uncertainty; and 
interactivity [8]. As the selection criteria are dichoto-
mous, eight possible categories exist (n  =  23) although 
only six categories were linked to modelling approach(es) 
as some combinations were deemed unrealistic. Kim 
et  al. further recommend that model choice should be 
based on not only the nature of the decision problem (e.g. 
research question, natural history and features of the dis-
ease) but on practical concerns such as data availability, 
an analyst’s experience and time [8].
The last framework, by Jit and Brisson [6], utilized a 
series of questions organized into a flowchart to highlight 
the key distinctions between static (referred to as cohort 
models) and dynamic models in the context of infectious 
disease modelling. According to the authors, infectious 
diseases have several complexities that make it unique 
compared to other illnesses: transmissibility (i.e. interac-
tion between infected and susceptible individuals); natu-
ral immunity; and the epidemiology of the illness (i.e. an 
infection proceeds through several stages, such as: sus-
ceptibility, latency/incubation, infectious/symptomatic 
and recovery) [6]. These distinctions result in the need 
for dynamic modelling when the force of infection is 
not constant over time. Instances include if an interven-
tion changes the profile of the infected individuals (e.g. 
increase pathogenicity or transmissibility by shifting the 
age profile of the disease) or induces selective evolution 
on a subset of the organisms (e.g. antibiotic resistance) 
[6].
Consistency between decision frameworks
Given that several decision frameworks were identified, 
it was of interest to assess the concordance in the frame-
works’ recommendations. To conduct this, the structural 
features were evaluated across frameworks to assess 
their consistency in how they categorize each modelling 
approach in terms of their structural traits. As previously 
mentioned, structural features are expected to remain 
the same across decision frameworks for each modelling 
approach since they are based on theories and facts.
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Table  5 presents the degree to which the decision 
frameworks are consistent in how they classify the struc-
tural assumptions specific to each modelling approach. 
As only two frameworks included agent-based models, 
both agreed that it is an individual-level approach that 
can incorporate interactions. System dynamics was seen 
as an aggregate-level approach that could handle inter-
actions. Amongst the frameworks that do discuss the 
mechanism of time, system dynamic was considered able 
to model at a discrete unit or continuously although their 
capacity for handling resource constraints has yet to be 
addressed. Markov microsimulations have been char-
acterized by the majority of the frameworks as an indi-
vidual-level approach with time handled discretely or 
continuously. Few frameworks have addressed first-order 
uncertainty and the capability of Markov microsimula-
tions in handling resource constraints except for one 
that suggested that microsimulations can assume unlim-
ited resources [7]. Disagreement between frameworks 
remained on whether it is capable of handling interaction. 
For discrete event simulation, of those that addressed 
resource constraints and first order uncertainty, they all 
agreed on its capacity to incorporate resource constraints 
and that it is stochastic. The majority considered discrete 
event simulation as being capable of handling interac-
tions between patients. However, discrepancies lay on 
how to classify the resolution of such models. For com-
partmental models, only the features of population reso-
lution, first order uncertainty and interactivity have been 
discussed so far with the sole agreement being that this 
approach can incorporate interactions (Table 5).
For traditional modelling approaches, an even greater 
degree of disagreements was observed in how structural 
features were specified. Most frameworks did not dis-
cuss the notion of resource constraints for decision trees. 
Of the frameworks that describe the dimension of time 
and interactivity, they were consistent in characterizing 
decision trees as static, fixed time horizon (i.e. untimed) 
models. However, for the remaining two structural fea-
tures (i.e. population resolution, first-order uncertainty), 
less clarity emerged. For Markov cohort models, as per 
its name, the frameworks all agreed that this modelling 
approach is not an individual-level modelling approach 
but rather focused at the aggregate-level. Markov cohort 
models were considered not capable of handling interac-
tion or resource constraints in most except in two of the 
frameworks (Table 5) [7, 12].
Discussion
Despite the prevalence in the use of traditional model-
ling approaches to conduct health economic evaluations, 
these frameworks all highlight the need for alternative 
modelling approaches under certain circumstances. 
For instance, discrete event simulation permits explicit 
incorporation of queuing theory and may be suit-
able if the question partly involves resource constraints. 
Agent-based models, on the other hand, can integrate 
agent-to-agent interactions and are thus suitable when 
behavior is considered an important characteristic with 
the problem at hand (e.g. infectious disease modelling). 
Indeed, it may be safe to extend that there is no single 
modelling approach that is capable of answering all types 
of research questions. HTA agencies and other policy 
organizations that rely on economic modelling to guide 
reimbursement and resources allocation decision-mak-
ing must therefore develop the capacity to construct and 
critically appraise models outside of what is considered 
the traditional modelling approaches.
Although several frameworks have been published 
to distinguish between modelling approaches, there is 
no clear over-arching or universally-accepted one. Each 
framework has, in fact, highlighted different selection 
criteria that may be of importance when choosing the 
most-suitable approach. A recurring theme that emerged 
across these frameworks is the necessity for the approach 
to reflect the underlying theory of the health condition 
and the characteristics of the health technologies being 
compared. The modelling approach selected should align 
with the purpose of the model and the level of detail 
desired with minimal complexity [4].
However, Table  5 highlighted a concerning observa-
tion: there is a general lack of agreement between the 
decision frameworks on how the structural features 
specific to each modelling approach are described. This 
suggests that, by using different frameworks, one may 
come to a different decision on what constitutes the most 
appropriate modelling approach. For instance, consider 
a model that is interested in exploring the cost-effective-
ness of therapies for lowering blood pressure in patients 
with essential hypertension in terms of the prevention of 
cardiovascular and cerebrovascular events. The model 
aims to simulate a cohort of patients with heterogeneous 
characteristics and, given the existing understanding of 
hypertension, the model must capture the impact of dif-
ferent risk factors on the development of clinical events 
as these risk factors evolve over time. Additional factors 
to consider for this decision problem is that resources 
will be assumed unlimited and that time will be handled 
discretely. Employing the six generic frameworks without 
consideration of the practical constraints, we find that 
four frameworks [7, 9–11] advise for a Markov micro-
simulation, one framework [13] recommends a Markov 
or discrete event simulation without specification on 
whether the Markov model is an aggregate-level or an 
individual-level model (i.e. microsimulation) while the 
last specifies for a discrete event simulation or a Markov 
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cohort model [12]. Other cases exist of applying these 
frameworks to a decision problem and encountering dif-
ferent recommendations in terms of which modelling 
approach would be recommended.
It may be that, in certain cases, these frameworks do 
not entirely represent what the authors would consider 
as best practice, but rather what is recommended and 
accepted practice in the jurisdiction in which they work 
(i.e. many countries now have national reimbursement 
bodies that provide guidelines on economic modelling 
and may influence the choices of how the researchers in 
those countries developed their framework). Indeed, dif-
ferent frameworks were found to address different sets 
of modelling approaches (Table 2). It would be expected 
that frameworks would characterize the structural fea-
tures specific to a particular modelling approach similarly 
although this was not observed (Table 5).
Despite this, another consistent recommendation 
emerged from these studies in that the decision of which 
modelling approach to select is dependent not only on 
the structural assumptions but often also on the practi-
cal considerations. It is rarely possible to consider one 
without the other. Even amongst the frameworks that 
solely incorporated structural features [6, 8, 10, 11], half 
included a separate discussion on the practical considera-
tions to modelling [8, 10]. The selection of the appropri-
ate modelling approach is therefore iterative. The clinical 
research question (i.e. characteristics of the disease and 
its intervention) dictates which structural features are 
important. This filters down the range of suitable mod-
elling approaches and subsequently, practical elements 
such as simplicity, computational efficiency, end-user 
requirements and transparency may impact the decision 
on the best-suited modelling approach.
One unresolved question remains: the trade-off 
between simplicity and internal validity. In most of 
the frameworks and in other broad economic evalua-
tion guidelines, the majority support the notion that the 
model structure should be kept as simple as possible [13, 
16]. Barton and colleagues mention that more complex 
models are only justifiable when the increased complex-
ity leads to more valid results [9]. Another interpretation 
to the above recommendation is that, when selecting a 
simpler technique, a modeller should ensure that any 
error incurred from omitting certain aspects of the dis-
ease and its intervention will not materially bias a study’s 
results [17]. But, how much simplification is possible 
without compromising a model’s validity? Unfortunately, 
this is not a straightforward issue as it is based on several 
factors including the nature of the decision problem (i.e. 
clinical condition and the treatment alternatives being 
modelled) and several practical considerations (e.g. avail-
able data, time and budget) [18]. Greater research and 
education is thus necessary for both modellers and deci-
sion-makers to better characterize and understand the 
implications of such a trade-off.
The observed discrepancy observed between frame-
works in the recommendations they provide on which 
modelling approach is appropriate leads to the question 
of whether selecting different modelling approaches do 
in fact impact the model’s results and conclusions? When 
does it truly matter which modelling approach is used? 
For instance, to what extent does patient heterogeneity 
have an impact such that a Markov microsimulation or a 
Markov cohort model would produce diverging results? 
Similarly, to what extent does queuing and constrained 
resources impact the cost-effectiveness of an intervention 
such that it warrants the need for a discrete event simula-
tion? These frameworks were all found to lack a sufficient 
evidence-base as most were based on general heuris-
tics. A means to answer the above questions empirically 
would be to assess a model’s validity. One approach, 
based on the concepts of cross-validation, would be to 
compare the results between highly-dependent mod-
els that employ different modelling approaches to oth-
erwise address the same research problem by  using the 
same data parameters and sharing common assumptions. 
Such exercises may inform when it empirically matters 
whether a particular modelling approach is selected and 
some of the early pioneers in such activities include the 
Mount Hood Challenge for diabetes modellers [19].
A recent systematic review was published focused on 
cross-validation work in health economic models, eval-
uating the impact of structural features on the choice 
of the modelling approach [20]. Population resolution 
was found to have minimal impact empirically as both 
aggregate- and individual-level models generated nearly 
identical results. Rather, consideration on this struc-
tural feature was relevant in terms of a practical trade-
off between validity and feasibility (e.g. individual-level 
models required fewer simplifying assumptions, thus 
increasing its face validity but at the expense of being 
more time- and data-intensive; and vice versa). In terms 
of the criterion of interactivity, infectious-disease models 
have consistently showed that, depending on the assump-
tions regarding the probability of disease exposure, 
dynamic and static models will produce dissimilar results 
and lead to opposing policy recommendations [20]. Fur-
ther research in this area is still required as it may pro-
vide the evidence that is necessary to better guide the 
development of evidence-based decision frameworks.
One challenge that arose over the course of this 
study was the heterogeneity in the terminologies 
employed to describe the modelling approaches. For 
instance, for Markov cohort model, Chick’s [11] frame-
work used the term “finite difference model” while the 
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original framework by Brennan referred to it as “simu-
lated Markov model” [13]. This was even more evident for 
Markov microsimulation as it was referred to by a wide 
range of terms including: “individual sampling model” [9, 
10], “patients evolve on discrete time grid” [11], “patient-
level simulation” [11], “Monte Carlo Markov models” 
[13], “Monte Carlo simulation/microsimulation” [8] and 
“First-order Markov model” [7]. This is concerning as 
continued use of unclear and inconsistent terminolo-
gies can hamper communication between modellers and 
mislead understanding on these frameworks. It is possi-
ble (and we acknowledge) that the differences observed 
between frameworks may not only lie with their recom-
mendations but may also be partly due to differences in 
their semantics. Given the cross-disciplinary nature of 
this field, greater effort is necessary to standardize the 
terminology that is being used. Some excellent work has 
emerged from ISPOR-SMDM good research practice 
guidelines [3–5] although much remains to be done.
A limitation with this study is that it focused mainly 
on literature from the health care context. As previously 
mentioned, the modelling approaches used in health eco-
nomic evaluations originated from the fields of math-
ematics, operations research and industrial engineering. 
Consequently, a vast and rich source of literature is likely 
to exist within those fields that have not been included 
in this study. By not including studies from other disci-
plines, this paper may not capture the decision frame-
works outside of health care. We acknowledge that this 
is a limitation to this study although it was necessary to 
restrict the literature search within the field of health to 
capture the decision criteria that are specifically relevant 
to the health context.
Conclusions
To reiterate, the aim of this systematic review was not 
to propose a new framework that unifies the existing 
frameworks or to provide support towards a single one. 
Rather, this review was intended to identify and criti-
cally appraise the collection of decision frameworks that 
are currently available to health economic modellers 
and their users. Although most were developed inde-
pendently, at a minimum, all frameworks were found 
to involve a comparison of the structural features as a 
means to distinguish between the approaches. Nearly all 
frameworks considered the criteria of population reso-
lution and interactivity; which may perhaps be indica-
tive as the absolute minimum needed to be considered 
when selecting a modelling approach. Furthermore, most 
authors explicitly considered or discussed the practicali-
ties to modelling as part of their framework. Emerging 
from this review, we find that the process of selecting 
an appropriate approach for health economic models 
involves the consideration of multiple criteria. One must 
not only align the nature of a given decision problem with 
the structural features of a modelling approach; practical 
constraints that are context-dependent must further be 
examined.
Although decision frameworks are intended to provide 
a systematic and transparent approach in which to pur-
sue the question of which modelling approach should be 
chosen, this review found a concerning lack of agreement 
between frameworks in terms of how structural elements 
are classified. Thus, by employing different frameworks, 
different recommendations may emerge. In this case, the 
use of decision frameworks may provide a false sense of 
confidence that the appropriate methods were employed 
for the conduct of an economic evaluation and blindly 
shut down any further debate on the process and the 
considerations for which a modelling approach was cho-
sen. It is intended that this work will hopefully open dia-
logue between researchers and policy-makers in terms 
of providing or requiring greater transparency on how 
a particular modelling approach is selected. Until better 
agreement exists amongst frameworks or more empiri-
cal research is conducted, we strongly recommend that 
modellers properly and transparently justify why a par-
ticular modelling approach was selected over the others. 
The choice of a modelling approach is an important and 
necessary step to any health economic modelling exercise 
with broad implications on the subsequent model devel-
opment and evaluation. Given its potential impact on a 
model’s validity, the choice should be carefully consid-
ered, debated and reported.
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